As dust set­tles on the Are­na buy­out, Pfiz­er ex­ec sug­gests com­pa­ny will pur­sue a more ag­gres­sive M&A strat­e­gy

Pfiz­er made a big splash in the M&A space Mon­day, an­nounc­ing a $6.7 bil­lion buy­out of Are­na Phar­ma­ceu­ti­cals to chase Bris­tol My­ers Squibb in the S1P race. But com­pa­ny ex­ecs sug­gest­ed the com­pa­ny isn’t fin­ished bring­ing on new as­sets.

In an in­vestor call out­lin­ing the Are­na ac­qui­si­tion, chief busi­ness in­no­va­tion of­fi­cer Aamir Ma­lik took a mo­ment to dis­cuss Pfiz­er’s growth plans go­ing for­ward. The strat­e­gy was made up of three pil­lars: ad­vanc­ing the in­ter­nal pipeline, con­tin­u­ing to pur­sue out­side op­por­tu­ni­ties and ex­plor­ing the com­bi­na­tion of tech­nol­o­gy and da­ta to “ac­cel­er­ate” growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER